82 related articles for article (PubMed ID: 11129284)
41. Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice.
Li L; Yuan YZ; Lu J; Xia L; Zhu Y; Zhang YP; Qiao MM
Gut; 2006 Feb; 55(2):259-65. PubMed ID: 16287901
[TBL] [Abstract][Full Text] [Related]
42. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
43. [Adenoviral vector expressing an antiangiogenic fragment of thrombospondin 1 inhibits the growth of K562 cell xenografts].
Liu P; Wang Y; Yang RC; Cai YL; Han ZC
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(6):485-8. PubMed ID: 12887763
[TBL] [Abstract][Full Text] [Related]
44. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
45. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model.
Cascante A; Abate-Daga D; Garcia-Rodríguez L; González JR; Alemany R; Fillat C
Gene Ther; 2007 Oct; 14(20):1471-80. PubMed ID: 17713568
[TBL] [Abstract][Full Text] [Related]
46. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
[TBL] [Abstract][Full Text] [Related]
47. An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo.
Iuliano R; Trapasso F; Le Pera I; Schepis F; Samà I; Clodomiro A; Dumon KR; Santoro M; Chiariotti L; Viglietto G; Fusco A
Cancer Res; 2003 Feb; 63(4):882-6. PubMed ID: 12591742
[TBL] [Abstract][Full Text] [Related]
48. Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model.
Kim SY; Yang YS; Hong KH; Jang KY; Chung MJ; Lee DY; Lee JC; Yi HK; Nam SY; Hwang PH
Oral Oncol; 2008 Apr; 44(4):383-92. PubMed ID: 17690006
[TBL] [Abstract][Full Text] [Related]
49. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.
Zhao P; Zhu YH; Wu JX; Liu RY; Zhu XY; Xiao X; Li HL; Huang BJ; Xie FJ; Chen JM; Ke ML; Huang W
Life Sci; 2007 Aug; 81(9):695-701. PubMed ID: 17714738
[TBL] [Abstract][Full Text] [Related]
50. Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma.
Gattacceca F; Pilatte Y; Billard C; Monnet I; Moritz S; Le Carrou J; Eloit M; Jaurand MC
Clin Cancer Res; 2002 Oct; 8(10):3298-304. PubMed ID: 12374702
[TBL] [Abstract][Full Text] [Related]
51. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
Kratzke RA; Wang X; Wong L; Kratzke MG; Green MR; Vokes EE; Vogelzang NJ; Kindler HL; Kern JA;
J Thorac Oncol; 2008 Apr; 3(4):417-21. PubMed ID: 18379362
[TBL] [Abstract][Full Text] [Related]
52. Adenovirus p16 gene therapy for prostate cancer.
Allay JA; Steiner MS; Zhang Y; Reed CP; Cockroft J; Lu Y
World J Urol; 2000 Apr; 18(2):111-20. PubMed ID: 10854145
[TBL] [Abstract][Full Text] [Related]
53. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma.
Smythe WR; Kaiser LR; Hwang HC; Amin KM; Pilewski JM; Eck SJ; Wilson JM; Albelda SM
Ann Thorac Surg; 1994 Jun; 57(6):1395-401. PubMed ID: 8010779
[TBL] [Abstract][Full Text] [Related]
54. [p16INK4a expression mediated by recombinant adenovirus can induce senescence of A549 cells].
Bai XY; Che FX; Chen XM; Meng LY; Zhou Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Mar; 18(1):54-8. PubMed ID: 15340528
[TBL] [Abstract][Full Text] [Related]
55. Gene therapy for malignant mesothelioma: current prospects and challenges.
Tagawa M; Tada Y; Shimada H; Hiroshima K
Cancer Gene Ther; 2013 Mar; 20(3):150-6. PubMed ID: 23392201
[TBL] [Abstract][Full Text] [Related]
56. VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery.
Adachi Y; Yoshio-Hoshino N; Aoki C; Nishimoto N
Anticancer Res; 2010 Jun; 30(6):1947-52. PubMed ID: 20651338
[TBL] [Abstract][Full Text] [Related]
57. Abnormalities of the P16INK4A gene in thyroid cancer cell lines.
Ivan M; Wynford-Thomas D; Jones CJ
Eur J Cancer; 1996 Dec; 32A(13):2369-70. PubMed ID: 9038627
[No Abstract] [Full Text] [Related]
58. CDK4/6 Inhibition Shows Clinical Activity in p16ink4A-Deficient Mesothelioma.
Cancer Discov; 2022 Apr; 12(4):885. PubMed ID: 35373278
[TBL] [Abstract][Full Text] [Related]
59. Cure of experimental human malignant mesothelioma in athymic mice by diphtheria toxin.
Raso V; McGrath J
J Natl Cancer Inst; 1989 Apr; 81(8):622-7. PubMed ID: 2704052
[TBL] [Abstract][Full Text] [Related]
60. Commentary: A chess game for mesothelioma treatment: Not checkmate yet!
Pass HI
J Thorac Cardiovasc Surg; 2023 Jan; 165(1):369-370. PubMed ID: 35227497
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
